Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Dr. Harry Spiera Retires after 60 Years in Rheumatology

Kurt Ullman  |  Issue: April 2018  |  April 26, 2018

Ulf Wittrock / shutterstock.com

Ulf Wittrock / shutterstock.com

When Harry Spiera, MD, stepped out of the New York University School of Medicine in 1958, rheumatology was in its infancy. Obviously, much has changed for both the physician and the specialty over the 58 years between then and his recent retirement.

“Early on, rheumatology was the most clinical of the specialties, because the science just wasn’t there yet,” says Dr. Spiera. “At that time, we were just starting to look at the rheumatic diseases in a serious and systematic way. That fascinated me.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Over the years, research has made great strides in identifying rheumatic diseases and, at least as importantly, their treatment. When he began his career, rheumatoid arthritis (RA) was almost always a crippling and debilitating disease. Now, it is possible to stabilize patients and stop the progression of the disease.

“Rheumatology is not just a job, it is a part of who he is,” says Robert Spiera, MD, of his father. Dr. Robert Speira is Harry’s son and the director of the Scleroderma and Vasculitis Center at the Hospital for Special Surgery in New York City. “He suffered with this patients, he had joy with his patients, and recognized that any interaction you have with a patient is deeply important to them and their families.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Groundbreaking Work in PMR

Father and son: Harry Spiera, MD (right), with Robert Spiera, MD (left)

Father and son: Harry Spiera, MD (right), with Robert Spiera, MD (left).

Dr. Harry Spiera contributed to the advancement of science of rheumatologic diseases via his groundbreaking work in polymyalgia rheumatica (PMR). Criteria had been established for diagnosing other illnesses, but he noted a subset of elderly patients who appeared to be in good health who suddenly complained of stiffness and pain in the shoulder and hips.

PMR affects 1% of those over 50 at some time in their lives. Before Dr. Spiera published his series on multiple American patients in the 1960s, the only other work in the field had been a few cases studies in Europe.

That first series of 15 patients has, over the years, led to PMR becoming a well understood and accepted disease. He calls it “the most interesting and clinically satisfying part of my career.”

“It was his skill as a hands-on clinician who was in the room and really listening to the patient that helped lead to the recognition of PMR as an important inflammatory condition of the elderly,” says Dr. Robert Spiera. “He saw people coming to him with pain, but with a different quality than usual. His ability to listen enabled him to realize he was looking at something that hadn’t been previously described.”

Page: 1 2 3 | Single Page
Share: 

Filed under:Profiles Tagged with:Dr. Harry SpieraPolymyalgia RheumaticaSLE Lupus Foundation

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    New Findings for Polymyalgia Rheumatica & Osteoarthritis

    December 1, 2022

    The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.

    Polymyalgia Rheumatica: New Tricks for an Old Disease

    January 29, 2024

    Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

    Permanent Vision Loss in Late Giant Cell Arteritis

    October 18, 2018

    Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences